Randomized controlled study of bicarbonate-enhanced transarterial chemoembolization and transarterial embolization in treatment of hepatocellular carcinoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006025

Enrollment

Unknown

Registered

2015-02-08

Start date

2015-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

bTACE:bicarbonate-enhanced transarterial chemoembolization

bTAE:bicarbonate-enhanced transarterial embolization

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Hepatocellular carcinoma is confirmed by tissue pathology or clinical diagnosis standard, and does not receive any therapy; 2. ECOG score 0-1; 3. HCC BCLC grading: B or C; 4. Child-Pugh score prior to therapy: A or B; 5. As judged by investigators, the patient can comply with the study protocol; 6. Patient voluntarily participates in this study, understands the process of the study, and is willing to sign the written consent form.

Exclusion criteria

Exclusion criteria: 1. HCC BCLC grading: 0, A or D; 2. Child-Pugh score prior to therapy: D; 3. Tumor invades liver and/or portal vein or their branches and there is evident vein artery shunt.

Design outcomes

Primary

Measure	Time frame
Tumor response rate;side effect;	—

Secondary

Measure	Time frame
Survival time;	—

Countries

China

Contacts

Public ContactHu Xun

huxun@zju.edu.cn+86 0571 87783868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 12, 2026